Chilblains-like lesions and SARS-CoV-2 in children: An overview in therapeutic approach

Dermatol Ther. 2021 Jan;34(1):e14502. doi: 10.1111/dth.14502. Epub 2020 Nov 10.

Abstract

SARS-CoV-2 (Severe Acute Respiratory Syndrome, Coronavirus, type 2) is the virus responsible for the global pandemic of Coronavirus disease 2019 (COVID-19) that began in China in December 2019. The variability of nasal olfactory symptoms in pediatric patients is interlinked with possible warning signs, including respiratory, gastrointestinal, ocular, or dermatological symptoms. Skin findings in patients with COVID-19 can range from petechiae to papulovesicular rashes to diffuse urticaria and can be confused with rashes of non-COVID-19 conditions. These lesions typically appear early during COVID-19 and are thought to be secondary to viral replication or circulating cytokines. Herein, we discuss two pediatric cases, presenting with skin lesions, which tested positive for SARS-CoV-2, thus, briefly reviewing current literature for similar reports and related management. Although these lesions heal spontaneously in most cases, an adequate "targeted" therapeutic approach can shorten the time and the discomfort of the skin disease.

Keywords: coronavirus disease 2019; pediatricssevere acute respiratory syndrome-Coronavirus type-2; therapy.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Chilblains
  • Child
  • China / epidemiology
  • Humans
  • SARS-CoV-2